Cancer-related tiredness (CRF) is a crippling yet all-too-common disease that has a negative impact on patients' quality of life while they are receiving treatment. There are currently no viable pharmaceutical therapies available for the constellation of symptoms that together constitute CRF.

In a new study led by Yale Cancer Center researchers at Yale School of Medicine, the team found that a metabolism-targeting drug called dichloroacetate (DCA) helped alleviate CRF in experimental models, without interfering with cancer treatments.

The findings are a pathway for future CRF research that may someday lead to a new therapy for patients. The results were published in the American Journal of Physiology-Endocrinology and Metabolism on Oct. 2.

"This study identifies dichloroacetate, an activator of glucose oxidation, as the first intervention, and particularly the first metabolism-focused intervention, to prevent the whole syndrome of cancer-related fatigue in preclinical models," said senior author Rachel Perry, who is a member of Yale Cancer Center.

Researchers used tumour-bearing experimental models to investigate the effectiveness of DCA in treating cancer-related fatigue for patients living with melanoma.

The group found that DCA did not affect the rates of tumour growth or compromise the effectiveness of immunotherapy or chemotherapy in two experimental cancer models.

DCA also significantly preserved physical function and motivation in experimental models with late-stage tumours.

The data suggests that DCA treatment may have several positive effects, including reducing oxidative stress in the muscle tissue of the tumour-bearing experimental model.

The researchers said DCA could be a practice-changing approach in the future when used as an adjuvant therapy to treat cancer-related fatigue.

"We hope that this research will provide the bedrock for future clinical trials using dichloroacetate an FDA-approved drug for another indication (lactic acidosis) to treat the debilitating syndrome of cancer-related fatigue," said Perry, who is also an assistant professor of medicine (endocrinology) and of cellular and molecular physiology at Yale School of Medicine.